Overview

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Allysta Pharmaceutical
Treatments:
Ophthalmic Solutions